CREB1 Antibody

What are the optimal applications for different types of CREB1 antibodies?

CREB1 antibodies are available in both monoclonal and polyclonal formats, each with specific advantages for different applications. Monoclonal antibodies like CREB1 Antibody (D-12) are mouse IgG2a kappa light chain antibodies that target specific amino acid sequences (254-327) of human CREB1. These antibodies are particularly reliable for detecting CREB1A, CREB1B, CREM, and ATF-1 isoforms across multiple species including mouse, rat, human, and avian species .

Polyclonal CREB1 antibodies, such as the rabbit-sourced CAB2431, target broader epitopes and can be useful for detecting different conformational states of the protein .

For application specificity:

• Western blot (WB): Both monoclonal and polyclonal antibodies work well with recommended dilutions of 1:500-1:2000

• Immunoprecipitation (IP): Monoclonal antibodies often provide cleaner results with less background

• Immunofluorescence (IF): Both types are effective, with monoclonal providing more consistent results

• Immunohistochemistry (IHC): Recommended dilutions range from 1:50-1:200

• ELISA: Both types can be used, with monoclonals offering higher specificity

The choice depends on your specific research question and whether you need to detect specific isoforms or all CREB1 variants.

How should CREB1 antibodies be validated for specificity in experimental systems?

Rigorous validation of CREB1 antibodies is essential for reliable experimental results. Recommended validation approaches include:

• Positive controls: Use cell lines known to express CREB1 such as NIH/3T3, MCF7, THP-1, or tissue samples like mouse brain, spleen, and spinal cord .

• Knockdown/knockout verification: Perform siRNA knockdown of CREB1 (as demonstrated in colorectal cancer cell lines) to confirm antibody specificity by showing reduced signal .

• Molecular weight verification: Confirm the observed molecular weight matches the expected range for CREB1 (43-46 kDa) rather than the calculated weight (35 kDa), as post-translational modifications affect migration .

• Cross-reactivity testing: Verify specificity across intended species, as many CREB1 antibodies work across human, mouse, and rat samples .

• Multiple application validation: Confirm antibody performance in multiple techniques (WB, IHC, IF) to ensure consistent detection.

• Phospho-specific validation: For phospho-CREB1 antibodies, validate using phosphatase treatments or stimulation with cAMP-inducing agents to confirm specificity to the phosphorylated form.

What storage and handling conditions preserve CREB1 antibody functionality?

Proper storage and handling of CREB1 antibodies are critical for maintaining their activity and specificity:

• Storage temperature: Store at -80°C for long-term preservation . Some antibodies may be stored at -20°C, but ultra-low temperature storage is preferable for extended shelf life.

• Buffer composition: CREB1 antibodies are typically supplied in PBS or PBS with stabilizing proteins. Avoid repeated freeze-thaw cycles which can lead to protein denaturation and loss of activity.

• Working aliquots: Prepare small working aliquots to avoid repeated freeze-thaw cycles of the main stock.

• Dilution preparation: When preparing working dilutions, use fresh, cold buffer systems appropriate for the application (e.g., TBST with 5% non-fat milk or BSA for Western blotting).

• Shelf life considerations: Even with optimal storage, antibody activity may decrease over time. It's advisable to validate older antibody lots against fresh controls periodically.

• Contamination prevention: Use sterile technique when handling antibody solutions to prevent microbial contamination.

How can CREB1 antibodies be utilized to investigate transcriptional regulation mechanisms?

CREB1 antibodies are valuable tools for elucidating complex transcriptional regulatory mechanisms:

• Chromatin immunoprecipitation (ChIP): CREB1 antibodies can identify genomic binding sites by precipitating CREB1-bound DNA fragments. This approach revealed that CREB1 directly binds to the promoter of ribonucleotide reductase subunit M2 (RRM2) in colorectal cancer cells, activating its transcription .

• Co-immunoprecipitation (Co-IP): CREB1 antibodies can pull down CREB1 along with interacting proteins, revealing important protein-protein interactions such as those with CREB-binding protein (CBP), TORC (transducers of regulated CREB activity), and PGC-1α .

• Sequential ChIP (Re-ChIP): This technique uses CREB1 antibodies in combination with antibodies against other transcription factors to identify co-occupancy at promoter regions.

• Proximity ligation assay (PLA): CREB1 antibodies can be used in PLA to visualize and quantify protein-protein interactions in situ.

• CREB1 phosphorylation analysis: Phospho-specific antibodies can monitor changes in CREB1 activation status following various stimuli, particularly important since CREB1 activity is regulated by phosphorylation at Ser-133 and Ser-142 .

Research has demonstrated that CREB1 enhances immunogenicity in HIV-1 vaccine studies, where CREB1 target gene expression was associated with reduced HIV-1 acquisition in clinical trials .

What approaches can be used to study CREB1 post-translational modifications using specific antibodies?

Post-translational modifications (PTMs) of CREB1 are critical for regulating its activity and can be studied using specialized antibodies and techniques:

• Phosphorylation analysis:

  • Use phospho-specific antibodies targeting key sites like Ser-133 (activation) and Ser-142 (circadian rhythm regulation)

  • Combine with phosphatase treatments as controls

  • Use kinase inhibitors to determine responsible signaling pathways

• SUMOylation detection:

  • CREB1 is sumoylated by SUMO1, particularly at Lys-304 which is required for nuclear localization

  • Use antibodies specific for SUMO-conjugated proteins in combination with CREB1 antibodies

  • Apply hypoxic conditions to enhance sumoylation for experimental analysis

• Ubiquitination analysis:

  • Study CREB1 degradation pathways using ubiquitin-specific antibodies

  • Apply proteasome inhibitors to stabilize ubiquitinated forms

• Sequential immunoprecipitation:

  • First immunoprecipitate with CREB1 antibodies

  • Then probe with antibodies against specific PTMs

• Mass spectrometry validation:

  • Immunoprecipitate CREB1 and analyze by mass spectrometry to identify novel PTMs

  • Compare PTM patterns under different cellular conditions

This approach is particularly valuable given that CREB1 function changes dramatically depending on its modification state, as seen in contexts like circadian rhythm regulation and hypoxic response .

How can CREB1 antibodies be employed in studying disease mechanisms?

CREB1 antibodies have proven invaluable for investigating disease mechanisms across various pathologies:

• Cancer research applications:

  • Expression analysis: Immunohistochemical staining of tissue microarrays has revealed CREB1 overexpression in multiple cancers, with semi-quantitative scoring methods correlating expression with clinical outcomes

  • Prognostic marker identification: High CREB1 expression correlates with decreased survival in colorectal cancer patients

  • Transcriptional target validation: CREB1 antibodies helped identify RRM2 as a direct transcriptional target promoting tumor aggressiveness

• Neurodegenerative disease investigations:

  • CREB1 antibodies can track CREB1 activity in models of neurodegeneration, where altered CREB1 function may contribute to pathology

  • Immunofluorescence applications can reveal subcellular localization changes in disease states

• Metabolic disorder studies:

  • CREB1 plays significant roles in energy metabolism and has been implicated in type II diabetes

  • Antibodies can monitor CREB1 interactions with PGC-1α in metabolic tissues

• Immunological research:

  • In HIV-1 vaccine studies, CREB1 target gene expression was linked to heightened protection from infection

  • CREB1-driven genes significantly distinguished participants who did not acquire HIV-1 post-vaccination in the RV144 trial

• Renal disease research:

  • In renal cell carcinoma, CREB1 exhibits an unusual negative correlation with tumor stage and grade, vascular invasion, and lymphovascular invasion

  • This differential role compared to other cancers highlights the tissue-specific functions of CREB1

What strategies can resolve inconsistent CREB1 antibody results across different experimental techniques?

Researchers frequently encounter disparities in CREB1 detection across different experimental platforms. Resolution strategies include:

• Antibody epitope considerations:

  • Different antibodies target distinct epitopes that may be masked in certain applications

  • Compare results using antibodies targeting different CREB1 regions (N-terminal vs. C-terminal)

  • For example, the D-12 antibody targets amino acids 254-327, which may be inaccessible in certain conformational states

• Fixation and sample preparation optimization:

  • For IHC/IF: Test different fixation methods (paraformaldehyde vs. methanol) as they differentially preserve epitopes

  • For WB: Compare reducing vs. non-reducing conditions, and vary denaturation temperatures

• Protein-protein interaction interference:

  • CREB1 interactions with proteins like CBP or TORC may mask antibody binding sites

  • Use detergent concentrations that disrupt protein complexes for Western blotting

• Isoform-specific detection:

  • CREB1 exists in multiple isoforms (CREB1A, CREB1B) that may be differentially detected

  • Verify which isoforms your antibody detects and compare with transcript analysis

• Post-translational modification interference:

  • Phosphorylation at Ser-133 or SUMOylation at Lys-304 may affect antibody binding

  • Use phosphatase treatment or deSUMOylation enzymes to standardize modification status

• Signal amplification methods:

  • For low expression samples, employ tyramide signal amplification for IHC/IF

  • For WB, consider using high-sensitivity chemiluminescent substrates

Empirical validation across multiple techniques and careful documentation of experimental conditions can help resolve such inconsistencies.

How should researchers interpret CREB1 expression data in the context of contradictory literature findings?

CREB1 expression and function vary significantly across tissue types and disease states, leading to apparently contradictory findings in the literature. Consider these interpretive frameworks:

• Tissue-specific contextual analysis:

  • CREB1 exhibits tissue-specific roles; for example, it shows seemingly contradictory functions in different cancer types

  • In renal cell carcinoma, CREB1 shows weakly negative correlations with tumor stage and grade, unlike its role in other cancers

  • In glioblastoma, CREB1 has been reported to both enhance cell growth and suppress proliferation in different contexts

• Quantification method standardization:

  • Standardize scoring methods for CREB1 expression in IHC

  • Consider ROC curve analysis to determine optimal cutoff points for CREB1 expression categorization

  • Evaluate both staining intensity and percentage of positive cells for more comprehensive assessment

• Isoform-specific analysis:

  • Different studies may detect different CREB1 isoforms

  • Specify which isoforms are detected in your experiments and compare to conflicting literature

• Integration with multi-omic data:

  • Combine protein expression data with transcriptomic analysis

  • Consider microRNA regulation (miR-22-3p, miR-26a-5p, miR-27a-3p, miR-221-3p) which may explain post-transcriptional control of CREB1

• Functional validation requirements:

  • Supplement expression data with functional assays to validate biological significance

  • For example, colorectal cancer studies confirmed CREB1-RRM2 pathway effects on proliferation, migration, and invasion through both in vitro and in vivo experiments

By addressing these considerations, researchers can better contextualize seemingly contradictory findings and contribute to a more nuanced understanding of CREB1 biology.

What controls are essential for accurate interpretation of CREB1 phosphorylation state analysis?

CREB1 phosphorylation, particularly at Ser-133, is a critical regulatory mechanism that affects its transcriptional activity. Essential controls include:

• Positive phosphorylation controls:

  • Stimulate cells with known activators of CREB1 phosphorylation (e.g., forskolin to elevate cAMP)

  • Include samples from tissues/cells where CREB1 is constitutively phosphorylated

  • Apply conditions that trigger STING-mediated pathways, as these modulate p-CREB1 activity

• Negative phosphorylation controls:

  • Treat samples with serine/threonine phosphatases (e.g., lambda phosphatase)

  • Include samples from serum-starved cells where basal phosphorylation is minimized

  • Use kinase inhibitors that block pathways leading to CREB1 phosphorylation

• Specificity controls for phospho-specific antibodies:

  • Use non-phosphorylated recombinant CREB1 protein as negative control

  • Compare results with total CREB1 antibodies to normalize phospho-signal

  • Validate with phospho-null mutants (S133A) when using cellular models

• Temporal controls:

  • Include time-course samples to capture the dynamic nature of CREB1 phosphorylation

  • CREB1 phosphorylation can be transient, so multiple time points are essential

• Subcellular localization controls:

  • Compare nuclear vs. cytoplasmic fractions, as phosphorylated CREB1 often translocates to the nucleus

  • Use immunofluorescence with phospho-specific antibodies to confirm localization patterns

• Cross-validation with functional readouts:

  • Monitor expression of known CREB1 target genes (e.g., RRM2) to confirm functional consequences of phosphorylation

  • Use reporter assays with CRE-containing promoters to verify transcriptional activity

These controls help distinguish specific phosphorylation signals from background and ensure accurate interpretation of CREB1 activation status across experimental conditions.

How should researchers design experiments to study CREB1's role in transcriptional regulation networks?

Designing robust experiments to elucidate CREB1's position in transcriptional networks requires multi-faceted approaches:

• Genome-wide binding site identification:

  • Perform ChIP-seq using validated CREB1 antibodies to map all genomic binding sites

  • Integrate with motif analysis to identify canonical and non-canonical CRE sites

  • Example finding: CREB1 directly binds the RRM2 promoter in colorectal cancer

• Transcriptome analysis following CREB1 modulation:

  • Conduct RNA-seq after CREB1 knockdown/overexpression to identify regulated genes

  • Compare acute vs. chronic CREB1 inhibition to distinguish direct from indirect targets

  • Validate with qRT-PCR for specific targets of interest

• Integrative network analysis:

  • Combine ChIP-seq and RNA-seq data to distinguish direct from indirect targets

  • Perform Gene Set Enrichment Analysis (GSEA) to identify CREB1-regulated pathways

  • The GSEA approach successfully identified CREB1 target genes that discriminate HIV-1 vaccine responders

• Co-factor dependency studies:

  • Use sequential ChIP or Co-IP to identify transcriptional co-factors

  • Investigate interactions with known partners like CBP and TORC

  • Perform knockdown studies of co-factors to determine their necessity for CREB1-mediated transcription

• Kinase-dependency mapping:

  • Use specific kinase inhibitors to determine which signaling pathways modulate CREB1 activity

  • Monitor phosphorylation status in parallel with transcriptional output

• Single-cell approaches:

  • Apply scRNA-seq following CREB1 modulation to capture heterogeneous responses

  • Combine with cellular indexing of transcriptomes and epitopes (CITE-seq) to correlate CREB1 protein levels with transcriptional output

• Validation in disease-relevant models:

  • Test findings in appropriate disease models where CREB1 dysregulation has been implicated

  • For example, colorectal cancer studies verified CREB1-RRM2 pathway effects on tumor aggressiveness using both in vitro and in vivo models

What experimental approaches can differentiate between direct and indirect effects of CREB1 on target gene expression?

Distinguishing direct from indirect CREB1 transcriptional regulation requires complementary experimental strategies:

• Chromatin occupancy analysis:

  • ChIP-qPCR targeting specific promoter regions containing putative CRE sites

  • ChIP-seq for genome-wide binding site identification

  • Motif analysis to confirm presence of canonical CRE sequences (TGACGTCA) or half-sites

  • Example: direct binding of CREB1 to RRM2 promoter was confirmed in colorectal cancer cells

• Time-resolved expression analysis:

  • Perform time-course experiments after CREB1 activation or inhibition

  • Direct targets typically show more rapid expression changes (within hours)

  • Use transcription inhibitors (e.g., actinomycin D) to distinguish primary from secondary responses

• Promoter activity assays:

  • Create reporter constructs containing wild-type and mutated CRE sites

  • Perform luciferase reporter assays to quantify CREB1-dependent transcriptional activation

  • Site-directed mutagenesis of CRE sites to confirm direct regulation

• Rapid CREB1 modulation techniques:

  • Employ inducible systems for acute CREB1 activation/inactivation

  • Use CREB1 dominant-negative constructs to acutely block function

  • Apply CREB1-specific small molecule inhibitors for temporal control

• In vitro DNA-binding assays:

  • Electrophoretic mobility shift assays (EMSA) to confirm direct CREB1 binding to target sequences

  • DNA-protein pulldown assays with biotinylated oligonucleotides containing CRE sites

• Nascent RNA analysis:

  • Implement nascent RNA sequencing techniques (e.g., GRO-seq, PRO-seq) to detect immediate transcriptional changes

  • These techniques capture RNA polymerase activity in real-time, identifying the earliest transcriptional responses

• Orthogonal validation:

  • Cross-reference experimental findings with public ChIP-seq datasets for CREB1

  • Compare results with established CREB1 target genes as positive controls

How can researchers effectively study CREB1 regulation by microRNAs in disease contexts?

MicroRNA regulation of CREB1 represents an important post-transcriptional control mechanism, particularly in disease states. Comprehensive experimental approaches include:

• MicroRNA target prediction and validation:

  • Use bioinformatic tools to predict miRNAs targeting CREB1 mRNA

  • Confirm direct targeting through luciferase reporter assays with wild-type and mutated CREB1 3'UTR

  • Four microRNAs (miR-22-3p, miR-26a-5p, miR-27a-3p, miR-221-3p) have been experimentally confirmed to regulate CREB1 in renal cell carcinoma

• MicroRNA-CREB1 correlation analysis in clinical samples:

  • Perform miRNA and CREB1 expression analysis in matched patient samples

  • Categorize samples by CREB1 protein expression and evaluate miRNA patterns

  • In RCC, miRNA expression was found to be inversely correlated with CREB1 protein levels

• Functional rescue experiments:

  • Overexpress CREB1 coding sequence without 3'UTR to rescue miRNA-mediated repression

  • Co-transfect miRNA inhibitors with CREB1 to demonstrate specificity

  • Measure downstream CREB1 target gene expression to confirm functional relevance

• miRNA enrichment assays:

  • Implement techniques like HITS-CLIP or PAR-CLIP to identify miRNAs directly bound to CREB1 mRNA in living cells

  • Combine with in silico analysis for comprehensive miRNA profiling

• Disease-specific miRNA-CREB1 interaction studies:

  • Compare miRNA regulation patterns across different disease contexts

  • Investigate whether disease-specific factors modulate miRNA-CREB1 interactions

  • For example, in RCC, the conventional understanding of CREB1 as an oncogene may be complicated by miRNA regulation

• Therapeutic targeting potential:

  • Evaluate the feasibility of manipulating specific miRNAs to modulate CREB1 expression in disease

  • Test miRNA mimics or inhibitors in appropriate disease models

  • Assess downstream effects on CREB1-regulated pathways and disease phenotypes

This multi-faceted approach can uncover disease-specific regulatory mechanisms and potentially identify novel therapeutic targets.

What methodological considerations are important when studying CREB1 in immune cell function and vaccine development?

Research on CREB1's role in immune responses requires specialized methodological approaches, particularly relevant to vaccine development:

• Immune cell-specific CREB1 activity measurement:

  • Monitor phospho-CREB1 levels in specific immune cell populations using flow cytometry

  • Track nuclear translocation of CREB1 in activated immune cells using imaging flow cytometry

  • Analyze CREB1 target gene expression in sorted immune cell populations

• Vaccine-induced CREB1 activation assessment:

  • The recombinant canarypox vector ALVAC+Alum was shown to induce CREB1 and its target genes, correlating with reduced HIV-1 acquisition

  • Compare CREB1 activation across different vaccine formulations (e.g., ALVAC+Alum vs. ALVAC+MF59)

  • Perform time-course analysis to determine optimal sampling timepoints post-vaccination

• Systems biology integration:

  • Implement Gene Set Enrichment Analysis (GSEA) to identify enrichment of CREB1 target genes

  • Correlate CREB1-driven gene signatures with protection outcomes in clinical trials

  • In the RV144 trial, CREB1 target gene expression discriminated participants who did not acquire HIV-1 post-vaccination

• Mechanistic pathway analysis:

  • Investigate the role of specific signaling pathways (e.g., STING pathway) in CREB1 activation

  • CREB1 gene expression likely results from direct cGAMP-modulated p-CREB1 activity

  • Monitor recruitment of CD4+ T cells and B cells to antigen presentation sites following CREB1 activation

• Adjuvant comparison studies:

  • Compare different adjuvant formulations for their ability to activate CREB1

  • Unlike ALVAC+Alum, ALVAC+MF59 showed significantly reduced CREB1 target gene expression, correlating with lack of protection in the HVTN702 trial

• Relevant cytokine/chemokine profiling:

  • Analyze CREB1-regulated cytokines and chemokines associated with protection

  • Use multiplexed assays to simultaneously measure multiple immune mediators